Compare AJANTA PHARMA with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA GSK PHARMA AJANTA PHARMA/
GSK PHARMA
 
P/E (TTM) x 22.9 32.9 69.5% View Chart
P/BV x 3.9 13.1 30.1% View Chart
Dividend Yield % 0.9 1.2 74.1%  

Financials

 AJANTA PHARMA   GSK PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
GSK PHARMA
Mar-19
AJANTA PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,4223,595 39.6%   
Low Rs8981,253 71.6%   
Sales per share (Unadj.) Rs233.5184.7 126.5%  
Earnings per share (Unadj.) Rs44.026.3 167.2%  
Cash flow per share (Unadj.) Rs52.229.2 178.8%  
Dividends per share (Unadj.) Rs9.0020.00 45.0%  
Dividend yield (eoy) %0.80.8 94.1%  
Book value per share (Unadj.) Rs255.1126.3 201.9%  
Shares outstanding (eoy) m88.02169.40 52.0%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.013.1 37.8%   
Avg P/E ratio x26.492.2 28.6%  
P/CF ratio (eoy) x22.283.1 26.8%  
Price / Book Value ratio x4.519.2 23.7%  
Dividend payout %20.576.1 26.9%   
Avg Mkt Cap Rs m102,081410,626 24.9%   
No. of employees `0006.85.0 137.1%   
Total wages/salary Rs m4,3075,372 80.2%   
Avg. sales/employee Rs Th3,022.66,306.7 47.9%   
Avg. wages/employee Rs Th633.41,083.1 58.5%   
Avg. net profit/employee Rs Th569.1898.0 63.4%   
INCOME DATA
Net Sales Rs m20,55431,281 65.7%  
Other income Rs m2111,023 20.6%   
Total revenues Rs m20,76532,304 64.3%   
Gross profit Rs m5,6646,009 94.3%  
Depreciation Rs m721486 148.3%   
Interest Rs m126 193.3%   
Profit before tax Rs m5,1436,540 78.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m1,2732,373 53.6%   
Profit after tax Rs m3,8704,454 86.9%  
Gross profit margin %27.619.2 143.5%  
Effective tax rate %24.836.3 68.2%   
Net profit margin %18.814.2 132.2%  
BALANCE SHEET DATA
Current assets Rs m11,81220,061 58.9%   
Current liabilities Rs m3,77614,543 26.0%   
Net working cap to sales %39.117.6 221.6%  
Current ratio x3.11.4 226.8%  
Inventory Days Days7757 136.3%  
Debtors Days Days8214 580.3%  
Net fixed assets Rs m14,39814,343 100.4%   
Share capital Rs m1751,694 10.4%   
"Free" reserves Rs m22,27719,704 113.1%   
Net worth Rs m22,45221,398 104.9%   
Long term debt Rs m72 330.0%   
Total assets Rs m26,96239,113 68.9%  
Interest coverage x444.31,091.0 40.7%   
Debt to equity ratio x00 314.5%  
Sales to assets ratio x0.80.8 95.3%   
Return on assets %14.411.4 126.2%  
Return on equity %17.220.8 82.8%  
Return on capital %23.031.9 71.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,682534 2,000.3%   
Fx outflow Rs m2,1027,091 29.6%   
Net fx Rs m8,580-6,557 -130.8%   
CASH FLOW
From Operations Rs m3,7483,994 93.8%  
From Investments Rs m-2,228-1,433 155.4%  
From Financial Activity Rs m-1,475-3,584 41.1%  
Net Cashflow Rs m45-1,023 -4.4%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 1.6 10.2 15.2%  
FIIs % 7.6 23.8 31.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 15.4 110.4%  
Shareholders   20,968 102,036 20.5%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ORCHID PHARMA LTD  WYETH LTD  TORRENT PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Frauds at Public Sector Banks, Upcoming IPOs, and Top Cues in Focus Today(Pre-Open)

India share markets ended their volatile day marginally lower yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 76 points (down 0.2%).

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

How the Modi Government is Helping My Top 7 Stocks(The 5 Minute Wrapup)

Nov 14, 2019

Recent reforms by the Modi government can give a big boost on your stocks, provided you buy the right ones.

I Think Nestle, HUL, and Asian Paints Could Give Low Returns(Profit Hunter)

Nov 15, 2019

If you think high quality stocks will continue their dream run forever, then you must read this now.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Nov 21, 2019 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - CADILA HEALTHCARE COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS